Format

Send to

Choose Destination
Nat Rev Drug Discov. 2018 Jan;17(1):1-2. doi: 10.1038/nrd.2017.218. Epub 2017 Nov 24.

Steps forward for cancer precision medicine.

Author information

1
Department of Pathology, Gasthuiszusters Antwerpen, Antwerp, Belgium.
2
Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium.
3
Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
4
Biorepositories and Biospecimen Research Branch; Division of Cancer Treatment and Diagnosis (DCTD); Cancer Therapy Evaluation Program; DCTD and Investigational Drug Branch; DCTD; NCI, NIH, Bethesda, Maryland, USA.
5
Erasmus MC Cancer Institute and Cancer Genomics Netherlands, Erasmus University Medical Center, Rotterdam, The Netherlands.
6
Wellcome Trust Sanger Institute, Cambridge, UK.
7
INSERM, University Paris-Sud, Univerisity Paris Saclay, Villejuif, France.
8
University Hospital Gasthuisberg, Leuven, Belgium.
9
EORTC Headquarters, 1200 Brussels, Belgium.

Abstract

The availability of targeted anticancer drugs and the relative affordability of genomic analyses has led to a growing expectation among patients with cancer that they can receive personalized treatment based on the genomic signature of their tumour. Here, we discuss some of the challenges and steps needed to bring such approaches into routine practice.

PMID:
29170471
DOI:
10.1038/nrd.2017.218
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center